Image Source: FDA |
The FDA Office of Generic Drugs has reported they are adding a second Division of Bioequivilance and a fourth Division of Chemistry. Director Helen Winkle released the plans in a memo from the Office of Pharmaceutical Science. According to Cutting Edge Information, they believe that the addition of a second Division of Bioequivilence could indicate that there has been an agreement reached after the initial Biologics Price Competition and Innovation Act passed Congress in 2009.
The Business of Biosimilars and Biobetters Conference will be addressing the abbreviated pathway head on, with a panel of experts examining the pros and cons of paying for expediting the process of the approval of generics.
How do you feel about paying to expedite the review process?
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment